RT Journal Article
SR Electronic
T1 Leukopenia as a Biomarker of Sunitinib Outcome in Advanced Renal Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3781
OP 3787
VO 34
IS 7
A1 TETSUO FUJITA
A1 YOJI WAKATABE
A1 KAZUMASA MATSUMOTO
A1 KEN-ICHI TABATA
A1 KAZUNARI YOSHIDA
A1 MASATSUGU IWAMURA
YR 2014
UL http://ar.iiarjournals.org/content/34/7/3781.abstract
AB Background: Sunitinib is known to cause a variety of adverse events. The aim of the present study was to investigate the prognostic significance of leukopenia for patients with advanced renal cell carcinoma (RCC) treated with sunitinib. Patients and Methods: Between December 2008 and January 2012, 44 consecutive patients with advanced RCC were treated with sunitinib. Adverse events that occurred during the study were identified. Cox proportional hazards regression analysis estimated the relative importance of the predictive factors for progression-free survival (PFS). Results: On multivariate analysis, leukopenia was a significant predictor of PFS (p=0.0185). The cohort with leukopenia comprised of 36 patients (81.8%) and the cohort without leukopenia of 8 patients (18.2%). Patients with leukopenia had a significantly higher response rate (p=0.0062) and significantly longer PFS (p<0.0001) compared to patients without leukopenia. Conclusion: Leukopenia is an independent, significant prognostic indicator for patients with advanced RCC treated with sunitinib.